Cui Jiujie, Shi Min, Xie Dacheng, Wei Daoyan, Jia Zhiliang, Zheng Shaojiang, Gao Yong, Huang Suyun, Xie Keping
Authors' Affiliations: Shanghai Key Laboratory of Pancreatic Diseases Research; Department of Oncology, Shanghai Jiaotong University Affiliated First People's Hospital; Department of General Surgery, Shanghai Jiaotong University Affiliated Ruijin Hospital; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai; Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Pathology Department of Affiliated Hospital, Hainan Medical College, Haikou, People's Republic of China; Departments of Gastroenterology, Hepatology, and Nutrition; and Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TexasAuthors' Affiliations: Shanghai Key Laboratory of Pancreatic Diseases Research; Department of Oncology, Shanghai Jiaotong University Affiliated First People's Hospital; Department of General Surgery, Shanghai Jiaotong University Affiliated Ruijin Hospital; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai; Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Pathology Department of Affiliated Hospital, Hainan Medical College, Haikou, People's Republic of China; Departments of Gastroenterology, Hepatology, and Nutrition; and Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TexasAuthors' Affiliations: Shanghai Key Laboratory of Pancreatic Diseases Research; Department of Oncology, Shanghai Jiaotong University Affiliated First People's Hospital; Department of General Surgery, Shanghai Jiaotong University Affiliated Ruijin Hospital; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai; Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Pathology Department of Affiliated Hospital, Hainan Medical College, Haikou, People's Republic of China; Departments of Gastroenterology, Hepatology, and Nutrition; and Neurosurg
Authors' Affiliations: Shanghai Key Laboratory of Pancreatic Diseases Research; Department of Oncology, Shanghai Jiaotong University Affiliated First People's Hospital; Department of General Surgery, Shanghai Jiaotong University Affiliated Ruijin Hospital; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai; Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Pathology Department of Affiliated Hospital, Hainan Medical College, Haikou, People's Republic of China; Departments of Gastroenterology, Hepatology, and Nutrition; and Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TexasAuthors' Affiliations: Shanghai Key Laboratory of Pancreatic Diseases Research; Department of Oncology, Shanghai Jiaotong University Affiliated First People's Hospital; Department of General Surgery, Shanghai Jiaotong University Affiliated Ruijin Hospital; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai; Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Pathology Department of Affiliated Hospital, Hainan Medical College, Haikou, People's Republic of China; Departments of Gastroenterology, Hepatology, and Nutrition; and Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res. 2014 May 15;20(10):2595-606. doi: 10.1158/1078-0432.CCR-13-2407. Epub 2014 Mar 14.
The transcription factor Forkhead box protein M1 (FOXM1) plays critical roles in cancer development and progression. However, the regulatory role and underlying mechanisms of FOXM1 in cancer metabolism are unknown. In this study, we characterized the regulation of aerobic glycolysis by FOXM1 and its impact on pancreatic cancer metabolism.
The effect of altered expression of FOXM1 on expression of glycolytic enzymes and tumor development and progression was examined using animal models of pancreatic cancer. Also, the underlying mechanisms of altered pancreatic cancer glycolysis were analyzed using in vitro molecular biology. The clinical relevance of aberrant metabolism caused by dysregulated FOXM1 signaling was determined using pancreatic tumor and normal pancreatic tissue specimens.
We found that FOXM1 did not markedly change the expression of most glycolytic enzymes except for phosphoglycerate kinase 1 (PGK-1) and lactate dehydrogenase A (LDHA). FOXM1 and LDHA were overexpressed concomitantly in pancreatic tumors and cancer cell lines. Increased expression of FOXM1 upregulated the expression of LDHA at both the mRNA and protein level and elevated LDH activity, lactate production, and glucose utilization, whereas reduced expression of FOXM1 did the opposite. Further studies demonstrated that FOXM1 bound directly to the LDHA promoter region and regulated the expression of the LDHA gene at the transcriptional level. Also, elevated FOXM1-LDHA signaling increased the pancreatic cancer cell growth and metastasis.
Dysregulated expression and activation of FOXM1 play important roles in aerobic glycolysis and tumorigenesis in patients with pancreatic cancer via transcriptional regulation of LDHA expression.
转录因子叉头框蛋白M1(FOXM1)在癌症发生和发展过程中发挥关键作用。然而,FOXM1在癌症代谢中的调控作用及潜在机制尚不清楚。在本研究中,我们对FOXM1对有氧糖酵解的调控及其对胰腺癌代谢的影响进行了表征。
利用胰腺癌动物模型研究了FOXM1表达改变对糖酵解酶表达以及肿瘤发生和发展的影响。此外,运用体外分子生物学方法分析了胰腺癌糖酵解改变的潜在机制。通过胰腺癌肿瘤组织和正常胰腺组织标本确定了FOXM1信号失调导致的异常代谢的临床相关性。
我们发现,除磷酸甘油酸激酶1(PGK-1)和乳酸脱氢酶A(LDHA)外,FOXM1并未显著改变大多数糖酵解酶的表达。FOXM1和LDHA在胰腺肿瘤和癌细胞系中同时过表达。FOXM1表达增加在mRNA和蛋白质水平均上调了LDHA的表达,并提高了乳酸脱氢酶活性、乳酸生成和葡萄糖利用,而FOXM1表达降低则产生相反的效果。进一步研究表明,FOXM1直接与LDHA启动子区域结合,并在转录水平调控LDHA基因的表达。此外,FOXM1-LDHA信号增强促进了胰腺癌细胞的生长和转移。
FOXM1表达失调和激活通过转录调控LDHA表达在胰腺癌患者的有氧糖酵解和肿瘤发生中发挥重要作用。